{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:13:06Z","timestamp":1767139986210,"version":"build-2238731810"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s00120-024-02413-4","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T09:02:20Z","timestamp":1724922140000},"page":"1162-1173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neue Systemtherapie beim fortgeschrittenen Harnblasenkarzinom","Novel systemic treatment options for advanced bladder cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"C.","family":"Aydogdu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Casuscelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"key":"2413_CR1","series-title":"Langversion","volume-title":"S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms","author":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf)","year":"2020","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, Awmf) (2020) S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms. Langversion, Bd. 2.0 (AWMF-Registrierungsnummer 032\/038OL)"},{"key":"2413_CR2","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.eururo.2012.02.028","volume":"61","author":"RE Hautmann","year":"2012","unstructured":"Hautmann\u00a0RE, De Petriconi\u00a0RC, Pfeiffer\u00a0C et\u00a0al (2012) Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 61:1039\u20131047","journal-title":"Eur Urol"},{"key":"2413_CR3","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(03)13580-5","volume":"361","author":"Anonymous","year":"2003","unstructured":"Anonymous (2003) Neoadjuvant chemotherapy in invasive bladder cancer: a\u00a0systematic review and meta-analysis. Lancet 361:1927\u20131934 (London, England)","journal-title":"Lancet"},{"key":"2413_CR4","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eururo.2005.04.006","volume":"48","author":"Anonymous","year":"2005","unstructured":"Anonymous (2005) Neoadjuvant chemotherapy in invasive bladder cancer: update of a\u00a0systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) meta-analysis collaboration. Eur Urol 48:202\u2013205 (discussion 205\u2013206)","journal-title":"Eur Urol"},{"key":"2413_CR5","doi-asserted-by":"crossref","first-page":"2185","DOI":"10.1007\/s00345-023-04478-w","volume":"41","author":"A Aydh","year":"2023","unstructured":"Aydh\u00a0A, Sari Motlagh\u00a0R, Alamri\u00a0A et\u00a0al (2023) Comparison between different neoadjuvant chemotherapy regimens and local therapy alone for bladder cancer: a\u00a0systematic review and network meta-analysis of oncologic outcomes. World J Urol 41:2185\u20132194","journal-title":"World J Urol"},{"key":"2413_CR6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","volume":"25","author":"C Pfister","year":"2024","unstructured":"Pfister\u00a0C, Gravis\u00a0G, Flechon\u00a0A et\u00a0al (2024) Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5\u00a0years in an open-label, randomised, phase\u00a03\u00a0study. Lancet Oncol 25:255\u2013264","journal-title":"Lancet Oncol"},{"key":"2413_CR7","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1200\/JCO.2011.34.8433","volume":"29","author":"MD Galsky","year":"2011","unstructured":"Galsky\u00a0MD, Hahn\u00a0NM, Rosenberg\u00a0J et\u00a0al (2011) Treatment of Patients With Metastatic Urothelial Cancer \u201cUnfit\u201d for Cisplatin-Based Chemotherapy. JCO 29:2432\u20132438","journal-title":"JCO"},{"key":"2413_CR8","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.eururo.2020.08.024","volume":"79","author":"C Pfister","year":"2021","unstructured":"Pfister\u00a0C, Gravis\u00a0G, Fl\u00e9chon\u00a0A et\u00a0al (2021) Randomized Phase\u00a0III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG\/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses. Eur Urol 79:214\u2013221","journal-title":"Eur Urol"},{"key":"2413_CR9","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","volume":"36","author":"A Necchi","year":"2018","unstructured":"Necchi\u00a0A, Anichini\u00a0A, Raggi\u00a0D et\u00a0al (2018) Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase\u00a0II Study. JCO 36:3353\u20133360","journal-title":"JCO"},{"key":"2413_CR10","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","volume":"25","author":"T Powles","year":"2019","unstructured":"Powles\u00a0T, Kockx\u00a0M, Rodriguez-Vida\u00a0A et\u00a0al (2019) Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 25:1706\u20131714","journal-title":"Nat Med"},{"key":"2413_CR11","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41591-020-1085-z","volume":"26","author":"N Van Dijk","year":"2020","unstructured":"Van Dijk\u00a0N, Gil-Jimenez\u00a0A, Silina\u00a0K et\u00a0al (2020) Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial. Nat Med 26:1839\u20131844","journal-title":"Nat Med"},{"key":"2413_CR12","doi-asserted-by":"crossref","first-page":"3967","DOI":"10.1200\/JCO.2005.05.3884","volume":"24","author":"BH Bochner","year":"2006","unstructured":"Bochner\u00a0BH, Kattan\u00a0MW, Vora\u00a0KC (2006) Postoperative nomogram predicting risk of recurrence after radical cystectomy for bladder cancer. J\u00a0Clin Oncol 24:3967\u20133972","journal-title":"J Clin Oncol"},{"key":"2413_CR13","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin\u00a0DF, Witjes\u00a0JA, Gschwend\u00a0JE et\u00a0al (2021) Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N\u00a0Engl J Med 384:2102\u20132114","journal-title":"N Engl J Med"},{"key":"2413_CR14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","volume":"22","author":"J Bellmunt","year":"2021","unstructured":"Bellmunt\u00a0J, Hussain\u00a0M, Gschwend\u00a0JE et\u00a0al (2021) Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a\u00a0multicentre, open-label, randomised, phase\u00a03\u00a0trial. Lancet Oncol 22:525\u2013537","journal-title":"Lancet Oncol"},{"key":"2413_CR15","doi-asserted-by":"crossref","first-page":"LBA531\u2013LBA531","DOI":"10.1200\/JCO.23.02233","volume":"42","author":"AB Apolo","year":"2024","unstructured":"Apolo\u00a0AB, Ballman\u00a0KV, Sonpavde\u00a0GP et\u00a0al (2024) AMBASSADOR Alliance A031501: Phase\u00a0III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. JCO 42:LBA531\u2013LBA531","journal-title":"JCO"},{"key":"2413_CR16","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma\u00a0P, Retz\u00a0M, Siefker-Radtke\u00a0A et\u00a0al (2017) Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a\u00a0multicentre, single-arm, phase\u00a02\u00a0trial. Lancet Oncol 18:312\u2013322","journal-title":"Lancet Oncol"},{"key":"2413_CR17","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Assaf\u00a0ZJ, Davarpanah\u00a0N et\u00a0al (2021) ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595:432\u2013437","journal-title":"Nature"},{"key":"2413_CR18","volume-title":"EAU","author":"MD Galsky","year":"2024","unstructured":"Galsky\u00a0MD, Witjes\u00a0JA, Gschwend\u00a0JE et\u00a0al (2024) Extended follow-up from CheckMate 274 including the first report of overall survival outcomes. In: EAU. In, Paris (2024)"},{"key":"2413_CR19","first-page":"TPS599-TPS599","volume":"38","author":"AO Siefker-Radtke","year":"2020","unstructured":"Siefker-Radtke\u00a0AO, Steinberg\u00a0GD, Bedke\u00a0J et\u00a0al (2020) Phase\u00a0III study of perioperative pembrolizumab (pembro) plus neoadjuvant chemotherapy (chemo) versus placebo plus neoadjuvant chemo in cisplatin-eligible patients (pts) with muscle-invasive bladder cancer (MIBC): KEYNOTE-866. JCO 38:TPS599-TPS599","journal-title":"JCO"},{"key":"2413_CR20","first-page":"TPS505-TPS505","volume":"39","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Meeks\u00a0JJ, Galsky\u00a0MD et\u00a0al (2021) A phase\u00a0III, randomized, open-label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine plus cisplatin for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (NIAGARA). JCO 39:TPS505-TPS505","journal-title":"JCO"},{"key":"2413_CR21","doi-asserted-by":"crossref","first-page":"TPS4587-TPS4587","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4587","volume":"39","author":"CJ Hoimes","year":"2021","unstructured":"Hoimes\u00a0CJ, Bedke\u00a0J, Loriot\u00a0Y et\u00a0al (2021) KEYNOTE-B15\/EV-304: Randomized phase\u00a03\u00a0study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC). JCO 39:TPS4587-TPS4587","journal-title":"JCO"},{"key":"2413_CR22","first-page":"TPS579-TPS579","volume":"40","author":"T Powles","year":"2022","unstructured":"Powles\u00a0T, Drakaki\u00a0A, Teoh\u00a0JY\u2011C et\u00a0al (2022) A phase\u00a03, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA). JCO 40:TPS579-TPS579","journal-title":"JCO"},{"key":"2413_CR23","first-page":"TPS585-TPS585","volume":"41","author":"A Necchi","year":"2023","unstructured":"Necchi\u00a0A, Bedke\u00a0J, Galsky\u00a0MD et\u00a0al (2023) Phase\u00a03 KEYNOTE-905\/EV-303: Perioperative pembrolizumab (pembro) or pembro + enfortumab vedotin (EV) for muscle-invasive bladder cancer (MIBC). JCO 41:TPS585-TPS585","journal-title":"JCO"},{"key":"2413_CR24","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/ijc.31833","volume":"144","author":"TJN Hermans","year":"2019","unstructured":"Hermans\u00a0TJN, Voskuilen\u00a0CS, Deelen\u00a0M et\u00a0al (2019) Superior efficacy of neoadjuvant chemotherapy and radical cystectomy in cT3-4aN0M0 compared to cT2N0M0 bladder cancer. Int J Cancer 144:1453\u20131459","journal-title":"Int J Cancer"},{"key":"2413_CR25","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1002\/cncr.10762","volume":"95","author":"J Bellmunt","year":"2002","unstructured":"Bellmunt\u00a0J, Albanell\u00a0J, Paz-Ares\u00a0L et\u00a0al (2002) Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a\u00a0phase\u00a0I\/II trial with paclitaxel, cisplatin, and gemcitabine. Cancer 95:751\u2013757","journal-title":"Cancer"},{"key":"2413_CR26","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H Von Der Maase","year":"2005","unstructured":"Von Der Maase\u00a0H, Sengelov\u00a0L, Roberts\u00a0JT et\u00a0al (2005) Long-term survival results of a\u00a0randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J\u00a0Clin Oncol 23:4602\u20134608","journal-title":"J Clin Oncol"},{"key":"2413_CR27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1200\/JCO.2011.37.3571","volume":"30","author":"M De Santis","year":"2012","unstructured":"De Santis\u00a0M, Bellmunt\u00a0J, Mead\u00a0G et\u00a0al (2012) Randomized phase\u00a0II\/III trial assessing gemcitabine\/carboplatin and methotrexate\/carboplatin\/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986. J\u00a0Clin Oncol 30:191\u2013199","journal-title":"J Clin Oncol"},{"key":"2413_CR28","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0022-5347(01)65459-4","volume":"156","author":"R Dreicer","year":"1996","unstructured":"Dreicer\u00a0R, Gustin\u00a0DM, See\u00a0WA et\u00a0al (1996) Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J\u00a0Urol 156:1606\u20131608","journal-title":"J Urol"},{"key":"2413_CR29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(17)30242-5","volume":"18","author":"J Garc\u00eda-Donas","year":"2017","unstructured":"Garc\u00eda-Donas\u00a0J, Font\u00a0A, P\u00e9rez-Valderrama\u00a0B et\u00a0al (2017) Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a\u00a0response after first-line chemotherapy (MAJA; SOGUG 2011\/02): a\u00a0multicentre, randomised, controlled, open-label, phase\u00a02\u00a0trial. Lancet Oncol 18:672\u2013681a","journal-title":"Lancet Oncol"},{"key":"2413_CR30","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0959-8049(98)00030-6","volume":"34","author":"V Lorusso","year":"1998","unstructured":"Lorusso\u00a0V, Pollera\u00a0CF, Antimi\u00a0M et\u00a0al (1998) A phase\u00a0II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 34:1208\u20131212","journal-title":"Eur J Cancer"},{"key":"2413_CR31","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.1200\/JCO.2001.19.12.3018","volume":"19","author":"AA Meluch","year":"2001","unstructured":"Meluch\u00a0AA, Greco\u00a0FA, Burris\u00a0HA 3rd et\u00a0al (2001) Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a\u00a0phase\u00a0II trial of the Minnie pearl cancer research network. J\u00a0Clin Oncol 19:3018\u20133024","journal-title":"J Clin Oncol"},{"key":"2413_CR32","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/1097-0142(20011215)92:12<2993::AID-CNCR10108>3.0.CO;2-2","volume":"92","author":"CN Sternberg","year":"2001","unstructured":"Sternberg\u00a0CN, Calabro\u00a0F, Pizzocaro\u00a0G et\u00a0al (2001) Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 92:2993\u20132998","journal-title":"Cancer"},{"key":"2413_CR33","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles\u00a0T, Park\u00a0SH, Voog\u00a0E et\u00a0al (2020) Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N\u00a0Engl J Med 383:1218\u20131230","journal-title":"N Engl J Med"},{"key":"2413_CR34","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/nature13904","volume":"515","author":"T Powles","year":"2014","unstructured":"Powles\u00a0T, Eder\u00a0JP, Fine\u00a0GD et\u00a0al (2014) MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515:558\u2013562","journal-title":"Nature"},{"key":"2413_CR35","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar\u00a0AV, Galsky\u00a0MD, Rosenberg\u00a0JE et\u00a0al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a\u00a0single-arm, multicentre, phase\u00a02\u00a0trial. Lancet 389:67\u201376","journal-title":"Lancet"},{"key":"2413_CR36","doi-asserted-by":"crossref","first-page":"4546","DOI":"10.1200\/JCO.2019.37.15_suppl.4546","volume":"37","author":"PH O\u2019donnell","year":"2019","unstructured":"O\u2019donnell\u00a0PH, Balar\u00a0AV, Vuky\u00a0J et\u00a0al (2019) KEYNOTE-052: Phase\u00a02\u00a0study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)\u2014Updated response and survival results. JCO 37:4546\u20134546","journal-title":"JCO"},{"key":"2413_CR37","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","volume":"22","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Cs\u0151szi\u00a0T, \u00d6zg\u00fcro\u011flu\u00a0M et\u00a0al (2021) Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a\u00a0randomised, open-label, phase\u00a03\u00a0trial. Lancet Oncol 22:931\u2013945","journal-title":"Lancet Oncol"},{"key":"2413_CR38","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/S1470-2045(20)30541-6","volume":"21","author":"T Powles","year":"2020","unstructured":"Powles\u00a0T, Van Der Heijden\u00a0MS, Castellano\u00a0D et\u00a0al (2020) Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a\u00a0randomised, open-label, multicentre, phase\u00a03\u00a0trial. Lancet Oncol 21:1574\u20131588","journal-title":"Lancet Oncol"},{"key":"2413_CR39","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","volume":"395","author":"MD Galsky","year":"2020","unstructured":"Galsky\u00a0MD, J\u00e1\u00a0AA, Bamias\u00a0A et\u00a0al (2020) Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a\u00a0multicentre, randomised, placebo-controlled phase\u00a03\u00a0trial. Lancet 395:1547\u20131557 (London, England)","journal-title":"Lancet"},{"key":"2413_CR40","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS Van Der Heijden","year":"2023","unstructured":"Van Der Heijden\u00a0MS, Sonpavde\u00a0G, Powles\u00a0T et\u00a0al (2023) Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N\u00a0Engl J Med 389:1778\u20131789","journal-title":"N Engl J Med"},{"key":"2413_CR41","doi-asserted-by":"crossref","first-page":"S1340","DOI":"10.1016\/j.annonc.2023.10.106","volume":"34","author":"TB Powles","year":"2023","unstructured":"Powles\u00a0TB, Perez Valderrama\u00a0B, Gupta\u00a0S et\u00a0al (2023) LBA6 EV-302\/KEYNOTE-A39: Open-label, randomized phase\u00a0III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la\/mUC). Ann Oncol 34:S1340","journal-title":"Ann Oncol"},{"key":"2413_CR42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/S1470-2045(17)30242-5","volume":"18","author":"J Garcia-Donas","year":"2017","unstructured":"Garcia-Donas\u00a0J, Font\u00a0A, Perez-Valderrama\u00a0B et\u00a0al (2017) Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a\u00a0response after first-line chemotherapy (MAJA; SOGUG 2011\/02): a\u00a0multicentre, randomised, controlled, open-label, phase\u00a02\u00a0trial. Lancet Oncol 18:672\u2013681a","journal-title":"Lancet Oncol"},{"key":"2413_CR43","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt\u00a0J, de Wit\u00a0R, Vaughn\u00a0DJ et\u00a0al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N\u00a0Engl J Med 376:1015\u20131026","journal-title":"N Engl J Med"},{"key":"2413_CR44","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg\u00a0JE, Hoffman-Censits\u00a0J, Powles\u00a0T et\u00a0al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a\u00a0single-arm, multicentre, phase\u00a02\u00a0trial. Lancet 387:1909\u20131920 (London, England)","journal-title":"Lancet"},{"key":"2413_CR45","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Rosenberg\u00a0JE, Sonpavde\u00a0GP et\u00a0al (2021) Enfortumab vedotin in previously treated advanced urothelial carcinoma. N\u00a0Engl J Med 384:1125\u20131135","journal-title":"N Engl J Med"},{"key":"2413_CR46","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa\u00a0ST, Balar\u00a0AV, Petrylak\u00a0DP et\u00a0al (2021) TROPHY-U-01: A\u00a0Phase\u00a0II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J\u00a0Clin Oncol 39:2474\u20132485","journal-title":"J Clin Oncol"},{"key":"2413_CR47","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","volume":"35","author":"Y Loriot","year":"2024","unstructured":"Loriot\u00a0Y, Petrylak\u00a0DP, Rezazadeh Kalebasty\u00a0A et\u00a0al (2024) TROPHY-U-01, a\u00a0phase\u00a0II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes. Ann Oncol 35:392\u2013401","journal-title":"Ann Oncol"},{"key":"2413_CR48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-20-2488","volume":"27","author":"X Sheng","year":"2021","unstructured":"Sheng\u00a0X, Yan\u00a0X, Wang\u00a0L et\u00a0al (2021) Open-label, multicenter, phase\u00a0II study of RC48-ADC, a\u00a0HER2-targeting antibody-drug conjugate, in patients with locally advanced or metastatic urothelial carcinoma. Clin Cancer Res 27:43\u201351","journal-title":"Clin Cancer Res"},{"key":"2413_CR49","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","volume":"381","author":"Y Loriot","year":"2019","unstructured":"Loriot\u00a0Y, Necchi\u00a0A, Park\u00a0SH et\u00a0al (2019) Erdafitinib in locally advanced or metastatic urothelial carcinoma. N\u00a0Engl J Med 381:338\u2013348","journal-title":"N Engl J Med"},{"key":"2413_CR50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S1470-2045(21)00660-4","volume":"23","author":"AO Siefker-Radtke","year":"2022","unstructured":"Siefker-Radtke\u00a0AO, Necchi\u00a0A, Park\u00a0SH et\u00a0al (2022) Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a\u00a0phase\u00a02\u00a0study. Lancet Oncol 23:248\u2013258","journal-title":"Lancet Oncol"},{"key":"2413_CR51","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00120-022-01983-5","volume":"62","author":"J Lewerich","year":"2023","unstructured":"Lewerich\u00a0J, Schmid\u00a0SC, Gschwend\u00a0JE et\u00a0al (2023) Value of immunotherapy in the perioperative treatment of localized muscle invasive bladder cancer. Urologie 62:279\u2013287","journal-title":"Urologie"}],"updated-by":[{"DOI":"10.1007\/s00120-024-02499-w","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T00:00:00Z","timestamp":1737936000000}}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02413-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02413-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02413-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T14:38:41Z","timestamp":1737988721000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02413-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":51,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2413"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02413-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"value":"2731-7064","type":"print"},{"value":"2731-7072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"11 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Der Originalbeitrag wurde korrigiert: Abbildung\u00a02 des Artikels war fehlerhaft.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Erratum","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Zu diesem Beitrag wurde ein Erratum ver\u00f6ffentlicht:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00120-024-02499-w","URL":"https:\/\/doi.org\/10.1007\/s00120-024-02499-w","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"Gem\u00e4\u00df den Richtlinien des Springer Medizin Verlags werden Autoren und Wissenschaftliche Leitung im Rahmen der Manuskripterstellung und Manuskriptfreigabe aufgefordert, eine vollst\u00e4ndige Erkl\u00e4rung zu ihren finanziellen und nichtfinanziellen Interessen abzugeben.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"C.\u00a0Aydogdu\n                      : A.\u00a0Finanzielle Interessen: C.\u00a0Aydogdu gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellter Urologe, Klinikum der Universit\u00e4t M\u00fcnchen, Urologische Klinik und Poliklinik, M\u00fcnchen | Mitgliedschaften: DGU, ASCO, AUA.\n                      I.\u00a0Brinkmann\n                      : A.\u00a0Finanzielle Interessen: I.\u00a0Brinkmann gibt an, dass kein finanzieller Interessenkonflikt besteht.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte Assistenz\u00e4rztin in der Klinik und Poliklinik f\u00fcr Urologie der LMU M\u00fcnchen | Mitgliedschaften: DGU, GeSRU, Die Chirurginnen e.\u202fV.\n                      J.\u00a0Casuscelli\n                      : A.\u00a0Finanzielle Interessen: Vortragshonorare oder Kostenerstattung als passiv Teilnehmende: Astellas, MSD, BMS, Bayer.\u00a0\u2013 B.\u00a0Nichtfinanzielle Interessen: angestellte Ober\u00e4rztin am Klinikum der Universit\u00e4t M\u00fcnchen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Autoren"}},{"value":"Die vollst\u00e4ndige Erkl\u00e4rung zum Interessenkonflikt der Wissenschaftlichen Leitung finden Sie am Kurs der zertifizierten Fortbildung auf\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Wissenschaftliche Leitung"}},{"value":"erkl\u00e4rt, dass f\u00fcr die Publikation dieser CME-Fortbildung keine Sponsorengelder an den Verlag flie\u00dfen.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Der Verlag"}}]}}